Markers of oxidative stress in dogs with heart failure

Abstract

We tested the hypothesis that indirect measures of oxidative stress (vitamin E, glutathione peroxidase, and malondialdehyde) differ in dogs in heart failure resulting from either myxomatous mitral valve disease or dilated cardiomyopathy. Dogs were classified according to the International Small Animal Cardiac Health Council (ISACHC) classification. Additionally, the effect of cardiac therapy on oxidative stress parameters and N-terminal pro-B-type natriuretic peptide (NT-proBNP) in advanced stages of congestive heart failure was investigated. There were no significant differences in oxidative stress parameters between healthy dogs and the individual groups of cardiac patients. Significantly lower malondialdehyde (MDA) was observed in the ISACHC II group in comparison to ISACHC groups III and I. A significant positive correlation in treated patients was observed between NT-proBNP and MDA, NT-proBNP and vitamin E, as well as between MDA and vitamin E (and lipid-standardized vitamin E). No significant differences in any of the measured parameters were found between treated and non-treated cardiac patients. Our results suggest an association between MDA (the extent of lipid peroxidation) and NT-proBNP, vitamin E and NT-proBNP, as well as between MDA and vitamin E in treated canine patients. Plasma vitamin E concentration was maintained in all stages of cardiovascular disease in these canine patients.

Antioxidant defence and oxidative stress markers in cats with asymptomatic and symptomatic hypertrophic cardiomyopathy: a pilot study

“…Contrary to our expectations, we did not find statistically significant differences in any of the oxidative stress parameters between cats without treatment and those in the course of pharmacological therapy. This result is consistent with the findings in dogs with cardiovascular disease [45]. The groups in the current study were small, and the pharmacotherapy was tailored to the patient needs and differed between individuals.…”

“…Numerous studies in humans found an increase in the concentration of MDA in patients with cardiovascular disease [41][42][43], and its association with the disease severity [42] and duration [43]. In contrast to those results, studies on dogs with dilated cardiomyopathy [44], and a mixed group of dogs with dilated cardiomyopathy and degenerative mitral valve disease [45,46] found no statistically significant differences between groups, which is consistent with our findings. It has also been suggested that standard treatment of heart failure affects the degree of lipid peroxidation.…”

Glutathione peroxidase of blood of dogs and cats with mammary tumors

“…Так, у крові анемічних собак активність ензиму значно ниж-ча, ніж у здорових тваринами (Kendall et al, 2017). Також показана залежність цього показника від форми анемії у собак (Gultekin and Voyvoda, 2017), але не виявлено статистично вірогідних відмінностей в активності GPx у собак з серцевою недостатністю (Verk et al, 2017). Активність ензиму в крові собак зростає в перші 60 хв після анестезії пропофолом чи севофолураном (Tomsič et al, 2018), та в перші 30 хв після анестезії комбінацією дексмедетомідину, мідазоламу, буторфанолу та атропіну (Feng et al, 2015), проте згодом цей показник приходить до норми.…”

Changes of inflammatory and oxidative stress biomarkers in dogs with different stages of heart failure

“…Increased levels of monocyte chemoattractant protein 1 (MCP-1) and decreased levels of interleukins have also been found in dogs with CHF (8), but there is no data available on how CRP or other in ammatory biomarkers can change in severe cases (6). Although increased levels of oxidative stress biomarkers are associated with cardiovascular diseases in dogs (14,15,16) and humans (17,18), there are no studies describing oxidative stress biomarkers such as total antioxidant capacity and thiol, and their relationships with in ammatory biomarkers and echocardiographic variables among the different stages of CHF.…”